SLGL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	15 208.00
Gjennomsnittsvolum	30 420.00
Markedsverdi	23.69M
EPS	$0 ( 2024-03-15 )
Neste inntjeningsdato	( $-0.150 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.840
ATR14	$0.0420 (4.94%)

Sol Gel Technologies Ltd Korrelasjon

10 Mest positive korrelasjoner
SIRI	0.864
CARE	0.862
FXNC	0.856
CFB	0.849
SFST	0.839
NFBK	0.839
HAIN	0.838
ACLS	0.836
OTEX	0.831
TTEC	0.829

10 Mest negative korrelasjoner
FRLA	-0.832
INCR	-0.832
VITL	-0.826
VTVT	-0.826
IXAQ	-0.819
TRMR	-0.818
TWLVU	-0.813
KNTK	-0.811
RIVE	-0.809
PWP	-0.807

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Sol Gel Technologies Ltd Økonomi

Annual	2023
Omsetning:	$1.55M
Bruttogevinst:	$1.21M (77.99 %)
EPS:	$-1.010

FY	2023
Omsetning:	$1.55M
Bruttogevinst:	$1.21M (77.99 %)
EPS:	$-1.010

FY	2022
Omsetning:	$3.88M
Bruttogevinst:	$-8.80M (-226.60 %)
EPS:	$-0.590

FY	2021
Omsetning:	$31.27M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$0.140

Financial Reports:

No articles found.

Sol Gel Technologies Ltd

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.